Marget Matthias, Bohlsen Dennis, Davarnia Parvin, Yoo-Ott Kyoung, Kabelitz Dieter, Skerra Arne, Steinmann Jörg
Institute of Immunology, Universitaetsklinikum Schleswig-Holstein, Campus Kiel, Michaelisstrasse 5, Kiel 24105, Germany.
Mol Immunol. 2005 Mar;42(5):643-9. doi: 10.1016/j.molimm.2004.09.013.
Major histocompatibility complex (MHC) class I molecules induce inhibitory signals on natural killer (NK) cells via killer cell immunoglobulin-like receptors (KIR). We recently reported a human single-chain antibody (scFv#1), which recognizes an epitope on HLA-Cw6 (genotype: 0602). Flow cytometry showed scFv#1 binding to HLA-Cw6 (strong) and also to HLA-Cw2, 4, 5 (very weak) but not to HLA-Cw1, 3, 7, 8. The presumptive epitope of the antibody fragment, which includes residues Asn77 and Lys80 was verified by introducing point mutations into HLA-Cw6 encoding cDNAs. Asn77 --> Ser77 (N77S) and Lys80- -> Asn80 (K80N) mutants of Cw6 lost scFv#1 binding capacity whereas an additional mutation at aa position 90 (Asp-->Ala, D90A) did not influence scFv#1 binding characteristics. Since residues 77 and 80 of HLA-C are directly involved in KIR/MHC interaction, we expected the induction of target cell lysis upon addition of scFv#1 when bringing NK and HLA-Cw6 positive cells together. To prove this interference, we performed Cr-release assays, using Cw0602 and mock-transfected K562 erythroleukemia cells as targets and freshly prepared peripheral blood NK cells as effector cells. scFv#1 appeared to influence KIR on ligand binding and restored lysis at low effector to target (E/T) ratios. Pan HLA class I antibody W6/32 did not show such effects. Taken together scFv#1 binding patterns with mutagenized HLA-Cw6 and Cr-release assays are strong evidence that the scFv#1 epitope on HLA-Cw6 is at or close to the binding site of CD158a.
主要组织相容性复合体(MHC)I类分子通过杀伤细胞免疫球蛋白样受体(KIR)在自然杀伤(NK)细胞上诱导抑制性信号。我们最近报道了一种人单链抗体(scFv#1),它识别HLA - Cw6(基因型:0602)上的一个表位。流式细胞术显示scFv#1与HLA - Cw6(强结合)以及HLA - Cw2、4、5(非常弱结合)结合,但不与HLA - Cw1、3、7、8结合。通过将点突变引入HLA - Cw6编码的cDNA中,验证了抗体片段的推定表位,该表位包括Asn77和Lys80残基。Cw6的Asn77→Ser77(N77S)和Lys80→Asn80(K80N)突变体失去了scFv#1结合能力,而第90位氨基酸的额外突变(Asp→Ala,D90A)不影响scFv#1的结合特性。由于HLA - C的77和80位残基直接参与KIR/MHC相互作用,我们预期当将NK细胞和HLA - Cw6阳性细胞放在一起并加入scFv#1时会诱导靶细胞裂解。为了证明这种干扰,我们进行了铬释放试验,使用Cw0602和mock转染的K562红白血病细胞作为靶细胞,新鲜制备的外周血NK细胞作为效应细胞。scFv#1似乎影响KIR的配体结合,并在低效应细胞与靶细胞(E/T)比例下恢复裂解。泛HLA I类抗体W6/32未显示出此类效应。综合scFv#1与诱变的HLA - Cw6的结合模式以及铬释放试验,有力地证明了HLA - Cw6上的scFv#1表位位于CD158a的结合位点或其附近。